blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3911652

EP3911652 - IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  10.02.2023
Database last updated on 11.09.2024
FormerRequest for examination was made
Status updated on  22.10.2021
FormerThe international publication has been made
Status updated on  25.07.2020
Formerunknown
Status updated on  13.03.2020
Most recent event   Tooltip23.01.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Biogen MA Inc.
225 Binney Street
Cambridge, MA 02142 / US
[2021/47]
Inventor(s)01 / HOPKINS, Brian, T.
c/o Biogen MA Inc.
225 Binney Street
Cambridge, MA 02142 / US
02 / PFAFFENBACH, Magnus
c/o Biogen MA Inc.
225 Binney Street
Cambridge, MA 02142 / US
03 / MAY-DRACKA, Tricia
c/o Biogen MA Inc.
225 Binney Street
Cambridge, MA 02142 / US
04 / EVANS, Ryan
c/o Biogen MA Inc.
225 Binney Street
Cambridge, MA 02142 / US
05 / GAO, Fang
c/o Biogen MA Inc.
225 Binney Street
Cambridge, MA 02142 / US
06 / ENYEDY, Istvan
c/o Biogen MA Inc.
225 Binney Street
Cambridge, MA 02142 / US
07 / XIN, Zhili
c/o Biogen MA Inc.
225 Binney Street
Cambridge, MA 02142 / US
08 / BOLDUC, Philippe
c/o Biogen MA Inc.
225 Binney Street
Cambridge, MA 02142 / US
09 / PETERSON, Emily, Anne
c/o Biogen MA Inc.
225 Binney Street
Cambridge, MA 02142 / US
[N/P]
Former [2021/47]01 / HOPKINS, Brian, T.
Cambridge, MA 02142 / US
02 / PFAFFENBACH, Magnus
Cambridge, MA 02142 / US
03 / MAY-DRACKA, Tricia
Cambridge, MA 02142 / US
04 / EVANS, Ryan
Cambridge, MA 02142 / US
05 / GAO, Fang
Cambridge, MA 02142 / US
06 / ENYEDY, Istvan
Cambridge, MA 02142 / US
07 / XIN, Zhili
Cambridge, MA 02142 / US
08 / BOLDUC, Philippe
Cambridge, MA 02142 / US
09 / PETERSON, Emily, Anne
Cambridge, MA 02142 / US
Representative(s)HGF
HGF Limited
1 City Walk
Leeds LS11 9DX / GB
[N/P]
Former [2021/47]HGF
1 City Walk
Leeds LS11 9DX / GB
Application number, filing date20707888.217.01.2020
[2021/47]
WO2020US14126
Priority number, dateUS201962794098P18.01.2019         Original published format: US 201962794098 P
[2021/47]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020150626
Date:23.07.2020
Language:EN
[2020/30]
Type: A1 Application with search report 
No.:EP3911652
Date:24.11.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 23.07.2020 takes the place of the publication of the European patent application.
[2021/47]
Search report(s)International search report - published on:EP23.07.2020
ClassificationIPC:C07D471/04, C07D487/04, C07D519/00, A61K31/437, A61K31/4985, A61K31/519, A61P9/00, A61P25/00, A61P29/00, A61P37/00
[2021/47]
CPC:
C07D471/04 (EP,US); A61P25/00 (EP); A61P29/00 (EP);
A61P37/00 (EP); A61P9/00 (EP); C07D487/04 (EP,US);
C07D519/00 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/47]
Extension statesBA13.08.2021
ME13.08.2021
Validation statesKH13.08.2021
MA13.08.2021
MD13.08.2021
TN13.08.2021
TitleGerman:IMIDAZO[1,2-A]PYRIDINYLDERIVATE ALS IRAK4-INHIBITOREN[2021/47]
English:IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS[2021/47]
French:DÉRIVÉS D'IMIDAZO[1,2-A]PYRIDINYLE SERVANT D'INHIBITEURS D'IRAK4[2021/47]
Entry into regional phase13.08.2021National basic fee paid 
13.08.2021Designation fee(s) paid 
13.08.2021Examination fee paid 
Examination procedure13.08.2021Examination requested  [2021/47]
13.08.2021Date on which the examining division has become responsible
28.03.2022Amendment by applicant (claims and/or description)
13.02.2023Despatch of a communication from the examining division (Time limit: M04)
13.06.2023Reply to a communication from the examining division
Fees paidRenewal fee
20.12.2021Renewal fee patent year 03
19.01.2023Renewal fee patent year 04
23.01.2024Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[X]US2008200494  (KISHINO HIROYUKI [JP], et al) [X] 2,5,30,31,37-41 * tables 1-3, 6; examples 9, 10, 17, 21, 26-28, 30, 33, 60, 65;; claims 20, 36, 37 *;
 [XA]WO2014209841  (HOFFMANN LA ROCHE [CH], et al) [X] 2,5,30,31,37 * examples A.5-A.7, 14, 32, 36, 40, 41, 44, 64-73;; claims 1, 31, 32 * [A] 1;
 [A]WO2015104688  (AURIGENE DISCOVERY TECH LTD [IN]) [A] 1-41 * example -; claims 1, 2, 16-23 *;
 [XA]WO2015197503  (HOFFMANN LA ROCHE [CH], et al) [X] 2,5,30,31,37 * examples D.1-D.3, 1, 2, 28, 47;; claims 1, 48, 49 * [A] 1;
 [E]WO2020035020  (ZHEJIANG HISUN PHARM CO LTD [CN]) [E] 1-41 * example -; claims 1-10 *;
 [A]  - W. MICHAEL SEGANISH, "Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015)", EXPERT OPINION ON THERAPEUTIC PATENTS, (2016), vol. 26, no. 8, doi:10.1080/13543776.2016.1202926, ISSN 1354-3776, pages 917 - 932, XP055308579 [A] 1-41 * the whole document *

DOI:   http://dx.doi.org/10.1080/13543776.2016.1202926
 [X]  - ESPÉRANCE MOINE ET AL, "A small-molecule cell-based screen led to the identification of biphenylimidazoazines with highly potent and broad-spectrum anti-apicomplexan activity", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, (2015), vol. 89, doi:10.1016/j.ejmech.2014.10.057, ISSN 0223-5234, pages 386 - 400, XP055585794 [X] 2,5,30,37 * page 389, table 1, compound Ttou269 *

DOI:   http://dx.doi.org/10.1016/j.ejmech.2014.10.057
 [XA]  - EMMANUEL PINARD ET AL, "Discovery of a Novel Class of Survival Motor Neuron 2 Splicing Modifiers for the Treatment of Spinal Muscular Atrophy", JOURNAL OF MEDICINAL CHEMISTRY, (2017), vol. 60, no. 10, doi:10.1021/acs.jmedchem.7b00406, ISSN 0022-2623, pages 4444 - 4457, XP055614701 [X] 2,5,30,31,37 * compounds 14, 15, 45, 48, 49, 51 * [A] 1

DOI:   http://dx.doi.org/10.1021/acs.jmedchem.7b00406
by applicantWO2004078163
 WO2018065962
    - COHEN, Current Opinion in Cell Biology, (20090000), vol. 21, pages 1 - 8
    - RINGWOODLI, Cytokine, (20080000), vol. 42, pages 1 - 7
    - CAO et al., Science, (19960000), vol. 271, no. 5252, pages 1128 - 31
    - MUZIO et al., Science, (19970000), vol. 278, no. 5343, pages 1612 - 5
    - WESCHE et al., J. Biol. Chem., (19990000), vol. 274, no. 27, pages 19403 - 10
    - LI et al., Proc. Natl. Acad. Sci. USA, (20020000), vol. 99, no. 8, pages 5567 - 5572
    - Remington's Pharmaceutical Sciences, Mack Publishing Company, (19900000), pages 1289 - 1329
    - T. KOUTSOKERAST. HEALY, "Systemic lupus erythematosus and lupus nephritis", Nat Rev Drug Discov, (20140000), vol. 13, no. 3, pages 173 - 174
    - LOUIS F. FIESERMARY FIESER, Reagents for Organic Synthesis, Wiley, (19670000), vol. 1-19
    - "Methoden der organischen Chemie", HOUBEN WEYL, Methods of Organic Chemistry, Georg Thieme Verlag, (19740000), vol. 15/1
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.